Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CRISPR THERAPEUTICS AG”

77 pharma patents match "CRISPR THERAPEUTICS AG" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 77
Index total 30,257
Page 2 / 4

Quick answer

This filtered view shows 77 pharmaceutical patents matching "CRISPR THERAPEUTICS AG" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

77 results for “CRISPR THERAPEUTICS AG” · 30,257 patents in full index Clear search

  1. US 11649438

    Methods and compositions for treating cancer

    CRISPR THERAPEUTICS AG · Granted May 16, 2023 · Expires May 11, 2043

    granted
  2. US 11622977

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Apr 11, 2023 · Expires Apr 6, 2043

    granted
  3. US 11591381

    Gene-edited natural killer cells

    CRISPR THERAPEUTICS AG · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  4. US 11578309

    Universal donor cells

    CRISPR THERAPEUTICS AG · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  5. US 11564997

    Materials and methods for treatment of friedreich ataxia and other related disorders

    CRISPR THERAPEUTICS AG · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted
  6. US 11566230

    Universal donor cells

    CRISPR THERAPEUTICS AG · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted
  7. US 11559588

    Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders

    CRISPR THERAPEUTICS AG · Granted Jan 24, 2023 · Expires Jan 19, 2043

    granted
  8. US 11529427

    Gene editing for hemophilia A with improved factor VIII expression

    CRISPR THERAPEUTICS AG · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted
  9. US 11497773

    Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence

    CRISPR THERAPEUTICS AG · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  10. US 11473060

    Compositions and methods for differentiating stem cells into NK cells

    CRISPR THERAPEUTICS AG · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  11. US 11471491

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  12. US 11459372

    Gene-edited natural killer cells

    CRISPR THERAPEUTICS AG · Granted Oct 4, 2022 · Expires Sep 29, 2042

    granted
  13. US 11433103

    Universal donor cells

    CRISPR THERAPEUTICS AG · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  14. US 11434505

    Universal donor cells

    CRISPR THERAPEUTICS AG · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted
  15. US 11407997

    Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders

    CRISPR THERAPEUTICS AG · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  16. US 11389481

    Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19

    CRISPR THERAPEUTICS AG · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  17. US 11332760

    Compositions and methods for genomic editing by insertion of donor polynucleotides

    CRISPR THERAPEUTICS AG · Granted May 17, 2022 · Expires May 12, 2042

    granted
  18. US 11298378

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted
  19. US 11254912

    Methods and compositions for treating cancer

    CRISPR THERAPEUTICS AG · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  20. US 11207351

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted
  21. US 11202802

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted
  22. US 11191783

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted
  23. US 11174469

    Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders

    CRISPR THERAPEUTICS AG · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  24. US 11166985

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted